Moderna Inc

MRNA

Company Profile

  • Business description

    Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

  • Contact

    200 Technology Square
    CambridgeMA02139
    USA

    T: +1 617 714-6500

    E: [email protected]

    https://www.modernatx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    5,600

Moderna Inc News & Analysis

stocks

33 undervalued US stocks

Here’s the new list of Morningstar’s top analyst picks for Q1 2023.
stocks

3 vaccine stocks that could get a boost on China outbreaks

Fresh pandemic fears may stoke demand for these vaccine makers.
stocks

COVID-19 vaccine booster plans match our expectations

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,450.9064.30-0.76%
CAC 407,216.8310.15-0.14%
DAX 4019,003.1130.53-0.16%
Dow JONES (US)43,958.1947.210.11%
FTSE 1008,030.334.560.06%
HKSE19,823.4523.43-0.12%
NASDAQ19,230.7450.66-0.26%
Nikkei 22538,721.66654.43-1.66%
NZX 50 Index12,623.2551.24-0.40%
S&P 5005,985.381.390.02%
S&P/ASX 2008,193.4062.20-0.75%
SSE Composite Index3,439.2817.310.51%

Market Movers